The goal of this study was to study human GE180 from the perspective of the previous animal observations.
With data from twenty-four participants having 18F-GE180 and 18F-AV45 PET scans, we evaluated the group differences of 18F-GE180 uptake between participants with and without cognitive impairment. An association analysis of 18F-GE180 and 18F-AV45 was then conducted to test if the relationship in humans is consistent with the two-stage association in AD mouse model.
Elevated 18F-GE180 was observed in participants with cognitive impairment compared to those with normal cognition. No regions showed reduced 18F-GE180 uptake. Consistent with mouse model, a two-stage association between 18F-GE180 and 18F-AV45 was observed.
18F-GE180 PET imaging showed promising utility in detecting pathological alterations in a symptomatic AD population. Consistent two-stage association between 18F-GE180 and amyloid PET in human and mouse suggested that 18F-GE180 uptake in human might be considerably influenced by microglial activation.
目的:本研究的目的是从先前动物观察的角度研究人类GE180。
方法:根据24名接受18F-GE180和18F-AV45PET扫描的参与者的数据,我们评估了有和无认知障碍参与者18F-GE180摄取的组间差异.然后进行18F-GE180和18F-AV45的关联分析以测试人类中的关系是否与AD小鼠模型中的两阶段关联一致。
结果:与认知正常的参与者相比,在认知障碍的参与者中观察到18F-GE180升高。没有区域显示18F-GE180摄取减少。与小鼠模型一致,观察到18F-GE180和18F-AV45之间存在两阶段关联.
结论:18F-GE180PET显像在检测有症状的AD人群的病理改变方面显示出很有希望的应用。在人和小鼠中18F-GE180和淀粉样蛋白PET之间的一致的两阶段关联表明,人的18F-GE180摄取可能受到小胶质细胞激活的很大影响。